Thera-SAbDab

LENZILUMAB

>   Structural Summary
TherapeuticLenzilumab
TargetCSF2
Heavy ChainQVQLVQSGAEVKKPGASVKVSCKASGYSFTNYYIHWVRQAPGQRLEWMGWINAGNGNTKYSQKFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCVRRQRFPYYFDYWGQGTLVTVSS
Light ChainEIVLTQSPATLSVSPGERATLSCRASQSVGTNVAWYQQKPGQAPRVLIYSTSSRATGITDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQFNKSPLTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (August '23)Phase-I%2FII
Estimated Status (August '23)Active
Recorded Developmental TechnologyHumaneering Technology
INN Year Proposed2014
INN Year Recommended2015
Companies InvolvedHumanigen%3BKaloBios Pharmaceuticals
Conditions Approvedna
Conditions ActiveDrug hypersensitivity%3BChronic myelomonocytic leukaemia%3BPrecursor cell lymphoblastic leukaemia-lymphoma%3BSolid tumours
Conditions DiscontinuedAsthma%3BRheumatoid arthritis
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy